The experimental antiviral drug for COVID-19 developed by Pfizer, Paxlovid reduces the risk of disease complication and death by 89%, Reuters reports.
A total of 1 219 patients with mild to moderate coronavirus infection participated in the study. It was found only 0.8% of study participants required hospitalization due to Covid complications, and none of them died.
The authors of the study note that it is recommended to take the drug as soon as possible after infection.
The publication notes that Pfizer produced by pill showed better results than the drug "Molnupiravir" developed by the pharmaceutical company Merck.
Pfizer will present the results of the midterm trials to the US Food and Drug Administration.
The pharmaceutical company explains that taking Paxlovid twice a day will be recommended if the medication is approved.
The UK became the first country in the world to approve the use of Molnupiravir for treatment against COVID-19.
